Osteosarcoma treatment - where do we stand? A state of the art review
- PMID: 24345772
- DOI: 10.1016/j.ctrv.2013.11.006
Osteosarcoma treatment - where do we stand? A state of the art review
Abstract
Long-term outcome for patients with high-grade osteosarcoma has improved with the addition of systemic chemotherapy, but subsequent progress has been less marked. Modern, multiagent, dose-intensive chemotherapy in conjunction with surgery achieves a 5-year event-free survival of 60-70% in extremity localized, non-metastatic disease. A major, as yet unsolved, problem is the poor prognosis for metastatic relapse or recurrence, and for patients with axial disease. This article reviews the current state of the art of systemic osteosarcoma therapy by focusing on the experiences of cooperative osteosarcoma groups. Also, we shed light on questions and challenges posed by the aggressiveness of the tumor, and we consider potential future directions that may be critical to progress in the prognosis of high-grade osteosarcoma.
Keywords: Interferon α; Metastatic disease; Mifamurtide; Osteosarcoma; Outcome; Prognostic factors; Systemic treatment.
Copyright © 2014. Published by Elsevier Ltd.
Similar articles
-
Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.Cancer. 2005 Sep 1;104(5):1100-9. doi: 10.1002/cncr.21263. Cancer. 2005. PMID: 16015627
-
Review of management issues in relapsed osteosarcoma.Expert Rev Anticancer Ther. 2014 Feb;14(2):151-61. doi: 10.1586/14737140.2014.863453. Epub 2013 Nov 26. Expert Rev Anticancer Ther. 2014. PMID: 24308680 Review.
-
Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma.Hematol Oncol Clin North Am. 2013 Oct;27(5):1021-48. doi: 10.1016/j.hoc.2013.07.012. Epub 2013 Aug 26. Hematol Oncol Clin North Am. 2013. PMID: 24093174 Review.
-
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.J Clin Oncol. 2005 Dec 1;23(34):8845-52. doi: 10.1200/JCO.2004.00.5785. Epub 2005 Oct 24. J Clin Oncol. 2005. PMID: 16246977 Clinical Trial.
-
Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients.Cancer. 2006 Jun 15;106(12):2701-6. doi: 10.1002/cncr.21937. Cancer. 2006. PMID: 16691623
Cited by
-
Incidence trends, overall survival, and metastasis prediction using multiple machine learning and deep learning techniques in pediatric and adolescent population with osteosarcoma and Ewing's sarcoma: nomogram and webpage.Clin Transl Oncol. 2024 Sep 27. doi: 10.1007/s12094-024-03717-9. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39333451
-
MiRNA encoded PTEN's impact on clinical-pathological features and prognosis in osteosarcoma: A systematic review and meta-analysis.PLoS One. 2024 Sep 19;19(9):e0304543. doi: 10.1371/journal.pone.0304543. eCollection 2024. PLoS One. 2024. PMID: 39298504 Free PMC article.
-
Multiple applications of metal-organic frameworks (MOFs) in the treatment of orthopedic diseases.Front Bioeng Biotechnol. 2024 Sep 4;12:1448010. doi: 10.3389/fbioe.2024.1448010. eCollection 2024. Front Bioeng Biotechnol. 2024. PMID: 39295846 Free PMC article. Review.
-
Machine Learning versus Cox Models for Predicting Overall Survival in Patients with Osteosarcoma: A Retrospective Analysis of the EURAMOS-1 Clinical Trial Data.Cancers (Basel). 2024 Aug 19;16(16):2880. doi: 10.3390/cancers16162880. Cancers (Basel). 2024. PMID: 39199651 Free PMC article.
-
Combination of Sintilimab and Anlotinib for Metastatic Osteosarcoma: A Case Report.Onco Targets Ther. 2024 Aug 13;17:661-665. doi: 10.2147/OTT.S464678. eCollection 2024. Onco Targets Ther. 2024. PMID: 39161887 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
